Clioquinol-1-benzyl-1,2,3,6-tetrahydropyridine hybrids show neuroprotection against okadaic acid-induced mitochondrial dysfunction and ROS damage, inhibition of AChE, metal chelating properties, modulation of AChE- and metal-induced Aβ aggregation, capacity to reduce p-Tau levels, improvement of cognitive and spatial memory in two AD models, and suppression of neuro-inflammation induced by Aβ1-42 in the cortex [123]. Here, MAPT is linked to Alzheimer disease.